What has been NCIs experience in funding cancer-related nanotechnology research and development?
The NCI has been a leader in funding cancer-related nanotechnology research for the past six years. The NCI has funded numerous projects that have demonstrated the potential for nanotechnology to be a major contributor to advances in cancer detection, therapy and prevention. NCI has been funding several highly successful cancer nanotechnology research projects via the Unconventional Innovations Program (UIP) (http://otir.nci.nih.gov/tech/uip.html) and the Innovative Molecular Analysis Technologies Program (http://otir.nci.nih.gov/tech/imat.html). The UIP began in 1999 and is targeted to invest $50 million over a ten year period. Applications to the Innovative Molecular Analysis Technologies (IMAT) program have been received in response to a solicitation since August 1998. Some examples of work being conducted by these projects include novel technologies for noninvasive detection, diagnosis, and treatment of cancer, and immunoliposome technology for tumor-targeted drug/probe delivery. •
Related Questions
- I have some experience in Research & Development in the areas of interest to DRDO. Can I join DRDO at a higher post?
- What has been NCI’s experience in funding cancer-related nanotechnology research and development?
- Does BEF provide funding for the research and development of new renewable energy technologies?
